Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Purchased by Paradiem LLC

Paradiem LLC boosted its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 38.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 107,031 shares of the company’s stock after acquiring an additional 29,847 shares during the period. Paradiem LLC owned 0.18% of Harmony Biosciences worth $3,457,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Pacer Advisors Inc. increased its stake in Harmony Biosciences by 534,795.2% during the fourth quarter. Pacer Advisors Inc. now owns 1,224,910 shares of the company’s stock valued at $39,565,000 after purchasing an additional 1,224,681 shares during the last quarter. Federated Hermes Inc. increased its stake in Harmony Biosciences by 2,132.8% during the fourth quarter. Federated Hermes Inc. now owns 525,337 shares of the company’s stock valued at $16,968,000 after purchasing an additional 501,809 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its stake in Harmony Biosciences by 18.3% during the third quarter. Adage Capital Partners GP L.L.C. now owns 1,420,000 shares of the company’s stock valued at $46,533,000 after purchasing an additional 220,000 shares during the last quarter. HealthInvest Partners AB bought a new stake in Harmony Biosciences during the fourth quarter valued at $4,684,000. Finally, Vanguard Group Inc. increased its stake in Harmony Biosciences by 2.5% during the third quarter. Vanguard Group Inc. now owns 3,684,152 shares of the company’s stock valued at $120,730,000 after purchasing an additional 88,295 shares during the last quarter. 86.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Jeffrey Dierks sold 11,979 shares of the company’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $32.00, for a total value of $383,328.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 30.80% of the company’s stock.

Harmony Biosciences Price Performance

HRMY stock traded up $0.39 during trading on Friday, hitting $29.32. The company had a trading volume of 376,165 shares, compared to its average volume of 370,404. The firm has a market capitalization of $1.67 billion, a price-to-earnings ratio of 13.83, a P/E/G ratio of 0.41 and a beta of 0.73. The business has a 50 day moving average of $31.37 and a 200 day moving average of $29.96. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $18.61 and a fifty-two week high of $39.26. The company has a current ratio of 2.75, a quick ratio of 2.72 and a debt-to-equity ratio of 0.38.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings data on Thursday, February 22nd. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.74 by ($0.29). The company had revenue of $168.40 million during the quarter, compared to analyst estimates of $168.90 million. Harmony Biosciences had a return on equity of 27.49% and a net margin of 22.16%. The business’s revenue for the quarter was up 31.3% compared to the same quarter last year. During the same period in the previous year, the company earned $1.01 EPS. As a group, research analysts predict that Harmony Biosciences Holdings, Inc. will post 3 earnings per share for the current year.

Analysts Set New Price Targets

HRMY has been the subject of several recent research reports. Needham & Company LLC reiterated a “buy” rating and set a $50.00 target price on shares of Harmony Biosciences in a research note on Tuesday, April 9th. Bank of America restated an “underperform” rating and set a $30.00 price target on shares of Harmony Biosciences in a research report on Tuesday, January 2nd. Mizuho lowered their price target on shares of Harmony Biosciences from $42.00 to $40.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. Cantor Fitzgerald restated an “overweight” rating and set a $49.00 price target on shares of Harmony Biosciences in a research report on Friday, April 12th. Finally, The Goldman Sachs Group upped their price target on shares of Harmony Biosciences from $25.00 to $28.00 and gave the stock a “sell” rating in a research report on Tuesday, January 9th. Two equities research analysts have rated the stock with a sell rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $40.63.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.